Solvent-cast direct-writing and electrospinning as a dual fabrication strategy for drug-eluting polymeric bioresorbable stents
Bioresorbable stents (BRS) are conceived to retain sufficient radial strength after implantation while releasing an antiproliferative drug in order to prevent vessel restenosis until complete resorption. Ongoing research trends involve the use of innovative manufacturing techniques to achieve thinne...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Politècnica de Catalunya (UPC) |
| Repositorio: | UPCommons. Portal del coneixement obert de la UPC |
| Idioma: | inglés |
| OAI Identifier: | oai:upcommons.upc.edu:2117/393155 |
| Acceso en línea: | https://hdl.handle.net/2117/393155 https://dx.doi.org/10.1016/j.addma.2023.103568 |
| Access Level: | acceso abierto |
| Palabra clave: | Polymeric composites Biomedical materials Solvent-cast direct-writing Bioresorbable stents Poly(l-lactic-co-¿-caprolactone) Electrospinning Everolimus Compostos polimèrics Materials biomèdics Àrees temàtiques de la UPC::Enginyeria dels materials |
| Sumario: | Bioresorbable stents (BRS) are conceived to retain sufficient radial strength after implantation while releasing an antiproliferative drug in order to prevent vessel restenosis until complete resorption. Ongoing research trends involve the use of innovative manufacturing techniques to achieve thinner struts combined with optimized local drug delivery. This work presents a combination of solvent-cast direct-writing (SC-DW) and electrospinning (ES) using poly-l-lactic acid (PLLA) and poly(l-lactic-co-¿-caprolactone) (PLCL) as a new approach to generate everolimus-eluting BRS for cardiovascular applications. A Design of Experiment (DoE) was conducted to determine the optimal parameters to obtain a homogeneous coating with high specific surface. Manufactured stents were characterized by means of mechanical tests and scanning electron microscopy (SEM), with everolimus release in accelerated conditions quantified through High Performance Liquid Chromatography (HPLC). Drug loading was achieved either encapsulated in the struts of the stent or in an electrospun PLCL membrane covering the stent. In the former case, everolimus release was found to be insufficient, less than 3% of total drug loading after 8 weeks. In the latter, everolimus release considerably increased with respect to drug-loaded 3D-printed stents, with over 50% release in the first 6 hours of the test. In conclusion, everolimus release from PLCL-coated 3D-printed stents would match the dose and timeframe required for in vivo applications, while providing thinner struts than SC-DW drug-loaded stents. |
|---|